{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:30:56Z","timestamp":1761921056781},"reference-count":50,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,5,15]]},"DOI":"10.2169\/internalmedicine.0514-22","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T22:15:45Z","timestamp":1664316945000},"page":"1415-1423","source":"Crossref","is-referenced-by-count":2,"title":["Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study"],"prefix":"10.2169","volume":"62","author":[{"given":"Masanori","family":"Fukushima","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamitsu","family":"Miyaaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Miuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Soyama","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 117: 659-676, 1963."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7: 608-614, 2001.","DOI":"10.1053\/jlts.2001.25453"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 16: 431-439, 2010.","DOI":"10.1002\/lt.22004"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Greeve M, Ferrell L, Kim M, et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology 17: 593-598, 1993.","DOI":"10.1002\/hep.1840170411"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32: 689-692, 2000.","DOI":"10.1053\/jhep.2000.17894"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29: 664-669, 1999.","DOI":"10.1002\/hep.510290347"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ayata G, Gordon FD, Lewis WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 33: 1098-1104, 2002.","DOI":"10.1053\/hupa.2002.129419"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104: 1755-1761, 1993.","DOI":"10.1016\/0016-5085(93)90656-W"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kaymakoglu S, Cakaloglu Y, Demir K, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol 28: 78-83, 1998.","DOI":"10.1016\/S0168-8278(98)80205-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 289: 3000-3004, 2003.","DOI":"10.1001\/jama.289.22.3000"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rinaldi L, Nascimbeni F, Giordano M, et al. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol 23: 1458-1468, 2017.","DOI":"10.3748\/wjg.v23.i8.1458"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Younossi Z, Stepanova M, Sanyal AJ, et al. The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options. J Hepatol 69: 1365-1370, 2018.","DOI":"10.1016\/j.jhep.2018.08.013"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? J Hepatol 68: 519-525, 2018.","DOI":"10.1016\/j.jhep.2017.11.018"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 57: 675-688, 2012.","DOI":"10.1016\/j.jhep.2012.04.015"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7: 363-373, 2001.","DOI":"10.1053\/jlts.2001.23011"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Morisco F, Pagliaro L, Caporaso N, et al. Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring. Dig Liver Dis 40: 585-598, 2008.","DOI":"10.1016\/j.dld.2008.02.003"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67: 328-357, 2018.","DOI":"10.1002\/hep.29367"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. [Definition and the diagnostic standard for metabolic syndrome--Committee to Evaluate Diagnostic Standards for Metabolic Syndrome]. Nihon Naika Gakkai Zasshi 94: 794-809, 2005 (in Japanese).","DOI":"10.2169\/naika.94.794"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363: 157-163, 2004.","DOI":"10.1016\/S0140-6736(03)15268-3"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56: 1751-1759, 2012.","DOI":"10.1002\/hep.25889"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005.","DOI":"10.1002\/hep.20701"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 85: 115-122, 1998.","DOI":"10.1152\/jappl.1998.85.1.115"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31: 1539-1547, 2013.","DOI":"10.1200\/JCO.2012.45.2722"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Goodpaster BH, Carlson CL, Visser M, et al. Attenuation of skeletal muscle and strength in the elderly: the health ABC study. J Appl Physiol (1985) 90: 2157-2165, 2001.","DOI":"10.1152\/jappl.2001.90.6.2157"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of &quot;seed and soil&quot; . Am J Gastroenterol 105: 613-620, 2010.","DOI":"10.1038\/ajg.2009.717"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Seo S, Maganti K, Khehra M, et al. <i>De novo<\/i> nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 13: 844-847, 2007.","DOI":"10.1002\/lt.20932"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Miyaaki H, Miuma S, Taura N, et al. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C. Hepatol Res 48: E335-E339, 2018.","DOI":"10.1111\/hepr.12920"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 178: 38-45, 2013.","DOI":"10.1093\/aje\/kws448"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 69: 896-904, 2018.","DOI":"10.1016\/j.jhep.2018.05.036"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 62: 1802-1805, 1996.","DOI":"10.1097\/00007890-199612270-00021"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 15: 1843-1851, 2009.","DOI":"10.1002\/lt.21943"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Patil DT, Yerian LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. Liver Transpl 18: 1147-1153, 2012.","DOI":"10.1002\/lt.23499"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Lim LG, Cheng CL, Wee A, et al. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int 27: 76-80, 2007.","DOI":"10.1111\/j.1478-3231.2006.01396.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hejlova I, Honsova E, Sticova E, et al. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl 22: 644-655, 2016.","DOI":"10.1002\/lt.24393"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Finkenstedt A, Auer C, Glodny B, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 11: 1667-1672, 2013.","DOI":"10.1016\/j.cgh.2013.06.025"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Miyaaki H, Miuma S, Taura N, et al. Risk factors and clinical course for liver steatosis or nonalcoholic steatohepatitis after living donor liver transplantation. Transplantation 103: 109-112, 2019.","DOI":"10.1097\/TP.0000000000002319"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 67: 862-873, 2017.","DOI":"10.1016\/j.jhep.2017.06.003"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kawaguchi T, Sumida Y, Umemura A, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 7: e38322, 2012.","DOI":"10.1371\/journal.pone.0038322"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai study. Am J Gastroenterol 108: 1299-1304, 2013.","DOI":"10.1038\/ajg.2013.104"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Honda Y, Yoneda M, Kessoku T, et al. Characteristics of non-obese non-alcoholic fatty liver disease: effect of genetic and environmental factors. Hepatol Res 46: 1011-1018, 2016.","DOI":"10.1111\/hepr.12648"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 19: 61-71.e15, 2021.","DOI":"10.1016\/j.cgh.2020.04.067"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Nishioji K, Sumida Y, Kamaguchi M, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol 50: 95-108, 2015.","DOI":"10.1007\/s00535-014-0948-9"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun 2: 48-57, 2018.","DOI":"10.1002\/hep4.1124"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Mikolasevic I, Orlic L, Hrstic I, Milic S. Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation. Hepatol Res 46: 841-852, 2016.","DOI":"10.1111\/hepr.12642"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 14: 1648-1654, 2008.","DOI":"10.1002\/lt.21588"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 18: 461-466, 2005.","DOI":"10.1111\/j.1432-2277.2004.00067.x"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Kitajima Y, Hyogo H, Sumida Y, et al. Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol 28: 1507-1514, 2013.","DOI":"10.1111\/jgh.12227"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Kamo N, Kaido T, Hamaguchi Y, et al. Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation. Clin Nutr 38: 2202-2209, 2019.","DOI":"10.1016\/j.clnu.2018.09.019"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 63: 131-140, 2015.","DOI":"10.1016\/j.jhep.2015.02.031"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. De Munck TJI, Verhaegh P, Lodewick T, et al. Myosteatosis in nonalcoholic fatty liver disease: an exploratory study. Clin Res Hepatol Gastroenterol 45: 101500, 2021.","DOI":"10.1016\/j.clinre.2020.06.021"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/10\/62_0514-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T03:26:42Z","timestamp":1684553202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/10\/62_0514-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0514-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"article-number":"0514-22"}}